Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Document › Details

Euronext N.V.. (7/13/16). "Press Release: GenSight Biologics Lists on Euronext to Become Europe's First Listed Gene Therapy Company. €40 Million Raised, Market Capitalisation €149 Million". Paris.

Region Region Paris
  Country France
Organisations Organisation Euronext Paris S.A.
  Group Euronext (Group)
  Organisation 2 GenSight Biologics S.A. (Euronext: SIGHT)
Products Product gene therapy
  Product 2 investment banking
Index term Index term GenSight Biologics–SEVERAL: investment, 201607 IPO €40m at €8/share at Euronext Paris
Person Person Gilly, Bernard (GenSight Biologics 201304 CEO + Co-founder before Fovea + Sofinnova Partners + Transgene)

EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for small and medium-sized companies (SMEs), today welcomed GenSight Biologics, a biopharmaceutical specialist in gene therapy, for its first day of trading on compartment C of Euronext’s regulated market in Paris.

Founded in 2012, GenSight Biologics is an innovative young company dedicated to discovering and developing gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system. Focusing initially on patients suffering from severe retinal diseases, GenSight Biologics’s current drug candidates are designed to offer patients sustainable functional visual recovery. The company’s stock market debut makes it the first listed gene therapy company in Europe.

GenSight Biologics (ticker code: SIGHT) was listed through the admission to trading on 13 July 2016 of 18,609,122 common shares, including 5,000,000 shares issued as part of a Global Offering[1], before the exercise of the over-allotment option.

GenSight Biologics’ admission and issuing price was set at €8 per share. Market capitalisation on the day of listing was €149 million. Listing raised a total of €40 million.

“We are delighted to announce GenSight Biologics’s successful listing on Euronext Paris—a key stage in our company’s growth,” said Bernard Gilly, founder and CEO of GenSight Biologics . “It puts us on track for greater international recognition and continued development of our drug candidates for the treatment of serious neurodegenerative retinal diseases. This success is all the more satisfying in that, despite today’s difficult market environment, we have strengthened our ties with leading institutional investors in the United States and in Europe. I would like to take this opportunity to extend warm thanks to all of our shareholders—old and new, partners and employees—for their support and contribution to our successful listing.”

[1]TheGlobal Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible vision loss in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection in order to offer patients a sustainable functional visual recovery

About Euronext

Euronext is the primary exchange in the Euro zone with more than 1 300 listed issuers worth more than €3.0 trillion in market capitalization as of end December 2015, an unmatched blue chip franchise consisting of 25 issuers in the EURO STOXX 50® benchmark and a strong diverse domestic and international client base.

Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. Euronext operates regulated markets, Alternext and the Free Market; in addition it offers EnterNext, which facilitates SMEs’ access to capital markets.


This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

Record changed: 2016-07-18


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Euronext (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top